NewcelX Ltd. (NCEL)
NASDAQ: NCELHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NCEL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $14.67M
- P/E (TTM)
- 4.88
- EPS (TTM)
- $0.52
- Dividend yield
- None
- 52-week range
- 1.83 – 5.12
- Day range
- 2.45 – 2.63
- Volume / Avg
- 5.61K / 13.34K
- Beta
- —
- Shares outstanding
- 5.78M
52-week range
NCEL stock today
NewcelX (NCEL) closed at $2.54 on Nov 20, down 5.58% (-$0.15), versus the S&P 500's 3.70% decline. Trading was light, with 5.61K shares changing hands, about 42% of the average daily volume. At this level, NCEL sits in the middle of its 52-week range of $1.83 to $5.12: 50.4% below the high, set on Apr 24, 2026 and 38.8% above the low.
NCEL is up 33.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 22.3%. NewcelX trades at 4.9x its trailing twelve-month earnings per share of $0.52.
Summary generated from market data by MetaCap's automated system. Methodology
About NewcelX
Company profileNewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Ronen Twito CPA
- Headquarters
- Kloten
- Employees
- 9
- IPO year
- 2021
- Website
- newcelx.com
Financial highlights
Full financialsNewcelX reported a net loss of $8.3 million, compared with a loss of $7.2 million a year earlier. Diluted earnings per share came in at $2.16, down from $2.43.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-8.30M | $-7.20M | $-3.33M | $-16.50M | $-11.95M |
| EPS (diluted) | $2.16 | $2.43 | $1.13 | $-33.52 | $-1.00 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$23.00+805.51%
- Strong buy 1
- Buy 0
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
NCEL news
All NCEL newsNewcelX peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CNTXContext Therapeutics Inc. | 0.16 | -5.10% | $14.70M | vs NCEL |
| CELUCelularity Inc. Class A | 0.463 | -1.05% | $15.02M | vs NCEL |
| CTXRCitius Pharmaceuticals Inc. | 0.5085 | +2.27% | $13.96M | vs NCEL |
| BYSIBeyondSpring Inc. | 0.33 | -24.49% | $13.66M | vs NCEL |
| ACTUActuate Therapeutics Inc. | 0.2253 | +5.38% | $13.60M | vs NCEL |
| QNRXQuoin Pharmaceuticals Ltd. ADR | 3.28 | -2.35% | $15.76M | vs NCEL |
| PBMPsyence Biomedical Ltd. | 2.97 | +3.85% | $15.80M | vs NCEL |
| ATOSAtossa Therapeutics Inc. | 1.60 | -8.86% | $15.92M | vs NCEL |
Indexes, lists and sector
NewcelX stock FAQ
What is NewcelX's stock price today?
NCEL last traded at $2.54 as of Nov 20, 4:00 PM EST, down 5.58% on the day. Prices are delayed at least 15 minutes.
Does NewcelX pay a dividend?
No. NewcelX does not currently pay a regular cash dividend.
What is NCEL's P/E ratio?
NCEL trades at a trailing P/E ratio of 4.88.
Who is NewcelX's CEO?
Mr. Ronen Twito CPA is the chief executive officer of NewcelX Ltd., which has about 9 employees.
Has NCEL ever split its stock?
Yes. The most recent NCEL stock split was a 1-for-10 split on Oct 31, 2025, one of 2 splits on record.
What is the NCEL 52-week high?
The 52-week high for NCEL is $5.12 and the 52-week low is $1.83. The stock is currently 50.4% below its high.